Loading...
XTAE
HDST-M
Market cap1mUSD
Oct 21, Last price  
539.00ILS
Name

HBL Hadasit Bio Holdings Ltd

Chart & Performance

D1W1MN
XTAE:HDST-M chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.06%
Rev. gr., 5y
-61.84%
Revenues
0k
000000360,000250,00023,00000000
Net income
-3m
L-88.14%
-22,045,000-10,861,000-15,190,000-5,674,000-16,645,000-1,634,00013,174,000-316,000-22,295,00031,208,00028,364,000-31,211,000-29,187,000-3,461,000
CFO
-2m
L-14.86%
-12,339,000-13,146,000-11,611,000-12,243,000-13,259,000-14,680,000-17,575,000-16,456,000-3,180,000-3,963,000-2,101,000-2,115,000-1,978,000-1,684,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.
URL
https://hbl.co.il/
IPO date
Dec 28, 2005
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT